Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due to AEs, and AE-related deaths.
An abstract is unavailable.
The FDA has approved revised drug labeling for fludarabine phosphate under Project Renewal.
Artificial intelligence diagnostic tools (AIDTs) in oncology show high image classification accuracy but limited clinical adoption. Their adoption could be enhanced by (i) using user…
Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.
Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.
An abstract is unavailable.
Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
This cohort study examines the institution-level and patient-level factors associated with mismatch repair and microsatellite testing for individuals with colorectal cancer.
P-BCMA-ALLO1 elicited high response rates and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.
